CMV-specific T Cell Immunity Test Indicated Prophylaxis of Letermovir After All-HSCT (clinicaltrials.gov) - Dec 16, 2025 - P3 | N=250 | Active, not recruiting | Sponsor: Ruijin Hospital | Recruiting ➔ Active, not recruiting | Phase classification: PN/A ➔ P3 | Trial primary completion date: Jun 2025 ➔ Jun 2026
Enrollment closed • Phase classification • Trial primary completion date • Bone Marrow Transplantation • Hematological Malignancies • Oncology • Transplantation
|